These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 32061861

  • 1. Characterizing the role of porin mutations in susceptibility of beta lactamase producing Klebsiella pneumoniae isolates to ceftaroline and ceftaroline-avibactam.
    Khalid A, Lubián AF, Ma L, Lin RCY, Iredell JR.
    Int J Infect Dis; 2020 Apr; 93():252-257. PubMed ID: 32061861
    [Abstract] [Full Text] [Related]

  • 2. Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum β-lactamases, and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant K. pneumoniae.
    Shields RK, Clancy CJ, Hao B, Chen L, Press EG, Iovine NM, Kreiswirth BN, Nguyen MH.
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5793-7. PubMed ID: 26169413
    [Abstract] [Full Text] [Related]

  • 3. Ceftazidime-avibactam activity against a challenge set of carbapenem-resistant Enterobacterales: Ompk36 L3 alterations and β-lactamases with ceftazidime hydrolytic activity lead to elevated MIC values.
    Castanheira M, Doyle TB, Hubler C, Sader HS, Mendes RE.
    Int J Antimicrob Agents; 2020 Jul; 56(1):106011. PubMed ID: 32417206
    [Abstract] [Full Text] [Related]

  • 4. Activity of ceftaroline-avibactam tested against Gram-negative organism populations, including strains expressing one or more β-lactamases and methicillin-resistant Staphylococcus aureus carrying various staphylococcal cassette chromosome mec types.
    Castanheira M, Sader HS, Farrell DJ, Mendes RE, Jones RN.
    Antimicrob Agents Chemother; 2012 Sep; 56(9):4779-85. PubMed ID: 22733066
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. High ceftazidime hydrolysis activity and porin OmpK35 deficiency contribute to the decreased susceptibility to ceftazidime/avibactam in KPC-producing Klebsiella pneumoniae.
    Shen Z, Ding B, Ye M, Wang P, Bi Y, Wu S, Xu X, Guo Q, Wang M.
    J Antimicrob Chemother; 2017 Jul 01; 72(7):1930-1936. PubMed ID: 28333323
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne blaKPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections.
    Shields RK, Chen L, Cheng S, Chavda KD, Press EG, Snyder A, Pandey R, Doi Y, Kreiswirth BN, Nguyen MH, Clancy CJ.
    Antimicrob Agents Chemother; 2017 Mar 01; 61(3):. PubMed ID: 28031201
    [Abstract] [Full Text] [Related]

  • 9. Characterization of β-lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline + avibactam (NXL104).
    Livermore DM, Mushtaq S, Barker K, Hope R, Warner M, Woodford N.
    J Antimicrob Chemother; 2012 Jun 01; 67(6):1354-8. PubMed ID: 22441578
    [Abstract] [Full Text] [Related]

  • 10. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae.
    Aktaş Z, Kayacan C, Oncul O.
    Int J Antimicrob Agents; 2012 Jan 01; 39(1):86-9. PubMed ID: 22041508
    [Abstract] [Full Text] [Related]

  • 11. In Vitro Selection of Meropenem Resistance among Ceftazidime-Avibactam-Resistant, Meropenem-Susceptible Klebsiella pneumoniae Isolates with Variant KPC-3 Carbapenemases.
    Shields RK, Nguyen MH, Press EG, Chen L, Kreiswirth BN, Clancy CJ.
    Antimicrob Agents Chemother; 2017 May 01; 61(5):. PubMed ID: 28242667
    [Abstract] [Full Text] [Related]

  • 12. Effect of Porins and blaKPC Expression on Activity of Imipenem with Relebactam in Klebsiella pneumoniae: Can Antibiotic Combinations Overcome Resistance?
    Balabanian G, Rose M, Manning N, Landman D, Quale J.
    Microb Drug Resist; 2018 Sep 01; 24(7):877-881. PubMed ID: 29782237
    [Abstract] [Full Text] [Related]

  • 13. In vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: results from the CANWARD surveillance study.
    Karlowsky JA, Adam HJ, Baxter MR, Lagacé-Wiens PR, Walkty AJ, Hoban DJ, Zhanel GG.
    Antimicrob Agents Chemother; 2013 Nov 01; 57(11):5600-11. PubMed ID: 23979759
    [Abstract] [Full Text] [Related]

  • 14. Activity of Ceftazidime-Avibactam Against Clinical Isolates of Klebsiella pneumoniae, Including KPC-Carrying Isolates, Endemic to New York City.
    Manning N, Balabanian G, Rose M, Landman D, Quale J.
    Microb Drug Resist; 2018 Nov 01; 24(1):35-39. PubMed ID: 28590820
    [Abstract] [Full Text] [Related]

  • 15. Supporting the ceftaroline fosamil/avibactam Enterobacteriaceae breakpoint determination using humanised in vivo exposures in a thigh model.
    Bhalodi AA, Crandon JL, Williams G, Nicolau DP.
    Int J Antimicrob Agents; 2014 Dec 01; 44(6):508-13. PubMed ID: 25278330
    [Abstract] [Full Text] [Related]

  • 16. Effects of KPC Variant and Porin Genotype on the In Vitro Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae.
    Wilson WR, Kline EG, Jones CE, Morder KT, Mettus RT, Doi Y, Nguyen MH, Clancy CJ, Shields RK.
    Antimicrob Agents Chemother; 2019 Mar 01; 63(3):. PubMed ID: 30617090
    [Abstract] [Full Text] [Related]

  • 17. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing Klebsiella pneumoniae.
    Zhang W, Guo Y, Li J, Zhang Y, Yang Y, Dong D, Zhu D, He P, Hu F.
    Antimicrob Resist Infect Control; 2018 Mar 01; 7():142. PubMed ID: 30479755
    [Abstract] [Full Text] [Related]

  • 18. Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae.
    Haidar G, Clancy CJ, Chen L, Samanta P, Shields RK, Kreiswirth BN, Nguyen MH.
    Antimicrob Agents Chemother; 2017 Sep 01; 61(9):. PubMed ID: 28630202
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Loss and gain of ceftazidime-avibactam susceptibility in a non-carbapenemase-producing K1-ST23 hypervirulent Klebsiella pneumoniae.
    Zhao J, Pu D, Li Z, Zhang Y, Liu X, Zhuo X, Lu B, Cao B.
    Virulence; 2024 Dec 01; 15(1):2348251. PubMed ID: 38697754
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.